Bio-economy news

Subscribe to Bio-economy news feed Bio-economy news
Business Wire - The global leader in news distribution
Updated: 24 min 14 sec ago

Dr. Gaetano Morelli Joins Altasciences Clinical Research’s Medical Team

6 hours 24 min ago
LAVAL, Quebec--(BUSINESS WIRE)--#GI--Dr. Gaetano Morelli, Director of Gastroenterology/Endoscopy at St. Mary's Hospital, joins Altasciences, a full service CRO with 25 years' experience.

CanniMed Topical Cream – An Innovative New Way to Help Patients

7 hours 24 min ago
SASKATOON, Saskatchewan--(BUSINESS WIRE)--CanniMed Topical Cream to be available as a kit that allows patients to mix at home their choice of CanniMed Oil Kalaya Carrier Base Gel

Antibe Therapeutics Engages Brand Institute to Advise on Nonproprietary Name for ATB-346

7 hours 24 min ago
TORONTO--(BUSINESS WIRE)--ANTIBE THERAPEUTICS ENGAGES BRAND INSTITUTE TO ADVISE ON NONPROPRIETARY NAME FOR ATB-346

CanniMed Therapeutics Reminds Shareholders to Vote the GREEN Proxy FOR the Acquisition of Newstrike Resources

7 hours 24 min ago
SASKATOON, Saskatchewan--(BUSINESS WIRE)--CanniMed Therapeutics Reminds Shareholders to Vote the GREEN Proxy FOR the Acquisition of Newstrike Resources

Premas, IncellDx Ink India Distribution Agreement

14 hours 24 min ago
NEW DELHI--(BUSINESS WIRE)--Premas Life Sciences Pvt., Ltd. and IncellDx, Inc. announced today they have signed an exclusive distribution agreement. The commercial partnership brings the power of cell by cell multiplex diagnostics for solid tumors carcinomas that can now be analyzed for molecular and protein biomarkers by flow cytometry. Included in the deal are: IncellDx's patented single-cell assays for quantifying PD-L1 on tumor cells and immune cell subtypes; patented single-cell assay for

CanniMed Therapeutics Inc. Announces Director Resignation

Tue, 16/01/2018 - 20:00
SASKATOON, Saskatchewan--(BUSINESS WIRE)--CanniMed Therapeutics Inc. Announces Director Resignation

A Second Leading Independent Proxy Advisor, Glass Lewis, Recommends CanniMed Shareholders Vote “FOR” the Newstrike Acquisition

Mon, 15/01/2018 - 08:00
SASKATOON, Saskatchewan--(BUSINESS WIRE)--A Second Leading Independent Proxy Advisor Glass Lewis Recommends CanniMed Shareholders Vote “FOR” the Newstrike Acquisition

CanniMed Therapeutics Inc. Launches $725 Million Lawsuit Alleging Multiple Claims of Wrongdoing Related to Aurora Hostile Bid

Fri, 12/01/2018 - 19:00
SASKATOON, Saskatchewan--(BUSINESS WIRE)--CanniMed Launches $725 Million Lawsuit Alleging Multiple Claims of Wrongdoing Related to Aurora Hostile Bid

Shiseido Acquires Breakthrough Technology from Olivo Laboratories

Thu, 11/01/2018 - 19:00
TOKYO & NEW YORK--(BUSINESS WIRE)--Shiseido Acquires "Second Skin" Technology from Olivo Laboratories.

Leading Independent Proxy Advisor ISS Recommends CanniMed Shareholders Vote “FOR” the Newstrike Acquisition

Thu, 11/01/2018 - 16:00
SASKATOON, Saskatchewan--(BUSINESS WIRE)--Leading Independent Proxy Advisor ISS Recommends CanniMed Shareholders Vote “FOR” the Newstrike Acquisition

STEMCELL Technologies Brings Groundbreaking Intestinal and Brain Organoid Culture Tools to the Global Research Community

Thu, 11/01/2018 - 10:00
VANCOUVER, British Columbia--(BUSINESS WIRE)--STEMCELL Technologies Inc. has released two product lines for organoid research that will enable scientists to create powerful models for studying human disease in the lab. Organoids, or 'mini-organs', are complex, 3D, in vitro culture models that maintain key structural, developmental and functional similarities to the corresponding intact organs. These innovative models provide specific insight into development and disease mechanisms, and offer op

Ferring and the Chinese Academy of Sciences Collaborate to Advance Research in Reproductive Medicine

Thu, 11/01/2018 - 02:00
SAINT-PREX, Switzerland--(BUSINESS WIRE)--Ferring and the Chinese Academy of Sciences collaborate to advance research in reproductive medicine

First Treatment for MERS Appears Safe in NIH Phase I Clinical Trial

Wed, 10/01/2018 - 16:00
SIOUX FALLS, S.D.--(BUSINESS WIRE)--#MERS--SAB Biotherapeutics' treatment for MERS appears safe in NIH Phase I study–shows broad potential for the novel human polyclonal immunotherapy platform.

CanniMed Therapeutics Inc. Announces Strategic International Cannabis Distribution Agreement with Fagron NV

Wed, 10/01/2018 - 08:00
SASKATOON, Saskatchewan--(BUSINESS WIRE)--CanniMed Therapeutics Inc. Announces Strategic International Cannabis Distribution Agreement with Fagron NV

Advanced Bionics Announces Health Canada Approval for the New HiFocus™ SlimJ Electrode

Tue, 09/01/2018 - 14:00
VALENCIA, Calif.--(BUSINESS WIRE)--#advancedbionics--Advanced Bionics (AB) announces Health Canada approval of the HiFocus™ SlimJ electrode. Health Canada approval follows approval by FDA (Food and Drug Administration) in the United States and TÜV (Technical Inspection Authority, Munich, Germany). Built on the proven HiFocus™ platform and developed with numerous surgeons from around the globe, the new SlimJ electrode features a thin, straight design for easy insertion through the round window or cochleostomy. Th

Enigma Biomedical Group Forms Australian Subsidiary To Further Research Efforts

Tue, 09/01/2018 - 13:00
TORONTO--(BUSINESS WIRE)--Enigma Biomedical Group today announced the formation of Enigma Biomedical Australia to support it’s ongoing research projects in Australia. The current research projects are for studies of an early stage imaging agent (MK-6240) to be used in Positron Emission Tomography (PET) scans for assessing the status and progression of neurofibrillary tangles (NFTs) in the brain. NFTs made up of aggregated tau protein are a hallmark of several neurodegenerative diseases, includi

Appili Therapeutics Licenses Bioterrorism Vaccine Rights

Tue, 09/01/2018 - 08:00
HALIFAX, Nova Scotia--(BUSINESS WIRE)--$IMV #AntibioticDeveloper--Appili Therapeutics Inc. (the “Company” or “Appili”), an anti-infective drug development company, announced today it has signed a licence agreement with the National Research Council of Canada (NRC) to develop ATI-1701, a vaccine to protect against Francisella tularensis, a potential bioterrorism agent that causes tularemia. The U.S. Centers for Disease Control and Prevention (CDC) ranks F. tularensis, the bacteria that causes tularemia, as a Category A pa

TTP Ventus Micropump Technology Enables Wearable Treatment for Sleep Apnea

Tue, 09/01/2018 - 06:00
CAMBRIDGE, England--(BUSINESS WIRE)--TTP Ventus announced that Sommetrics is using its Disc Pump to enable aerSleep™, a novel negative-pressure system for the treatment of sleep apnea.

CanniMed Therapeutics Inc. and Up Cannabis Inc. (Wholly-Owned Licensed Producer of Newstrike Resources Ltd.) Applaud the Province of Saskatchewan on Legalization Framework

Mon, 08/01/2018 - 17:00
SASKATOON, Saskatchewan & OAKVILLE, Ontario--(BUSINESS WIRE)--CanniMed and Up Cannabis Applaud Province of Saskatchewan on Legalization Framework

MedX Health Corp. Announces Proposed Private Placement

Mon, 08/01/2018 - 17:00
MISSISSAUGA, Ontario--(BUSINESS WIRE)--MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) announces that it intends to raise up to a further $1,500,000 from accredited investors, by issuance of up to 12,500,000 Units, at $0.12 per Unit. Upon closing, this proposed placement will complete the amount of the financing originally announced in March, 2017, at which time the proposed placement was being offered on a brokered basis. The current portion of the proposed financing is being offered

Pages